person · Reporting owner
Flagship Ventures Opportunities Fund I, L.P.
Disclosed activity across 5 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axcella Health Inc.AXLA · Entity 116059 | 10% owner | October 13, 2022 | October 17, 2022 |
| Evelo Biosciences, Inc.EVLO · Entity 108468 | 10% owner | May 27, 2022 | June 01, 2022 |
| Foghorn Therapeutics Inc.FHTX · Entity 5820 | Director · 10% owner | January 13, 2026 | January 15, 2026 |
| Kaleido Biosciences, Inc.KLDO · Entity 129745 | 10% owner | February 08, 2021 | February 10, 2021 |
| Rubius Therapeutics, Inc.RUBY · Entity 116417 | 10% owner | March 19, 2021 | March 23, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axcella Health Inc.
Report date October 13, 2022 · Filed October 17, 2022
Jointly reported with Flagship Ventures Fund IV General Partner LLC, Flagship Ventures Fund IV, L.P., Flagship Ventures Opportunities Fund I General Partner LLC, Afeyan Noubar
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Ventures Fund IV, L.P. | 14,101,638 |
Last balance in matching sequence
After 2022-10-13 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2022-10-13 · Purchase · Acquired 2,743,902 · Balance 11,344,305 F1: On October 13, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") and FPA, L.P. ("FPA Fund") purchased 2,743,902 shares, 914,634 shares and 3,048,780 shares, respectively, of the Issuer's Common Stock in a registered direct offering (the "October 2022 Offering") at a price of $1.64 per share pursuant to a Securities Purchase Agreement dated October 13, 2022. F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Row 2 · 2022-10-13 · Purchase · Acquired 2,757,333 · Balance 14,101,638 F3: Represents shares of Common Stock issued upon conversion of unsecured convertible promissory notes (the "Notes") previously held by Flagship Fund IV and Flagship Opportunities I that were issued pursuant to the terms of the Securities Purchase Agreement dated September 20, 2022. In connection with the October 2022 Offering, the conversion price of the Notes became fixed at $1.64 and the outstanding principal plus accrued interest of the Notes held by Flagship Fund IV and Flagship Opportunities I automatically converted into 2,757,333 shares and 919,111 shares, respectively, of the Issuer's Common Stock. F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Ventures Opportunities I, L.P. | 6,299,611 |
Last balance in matching sequence
After 2022-10-13 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 3 · 2022-10-13 · Purchase · Acquired 914,634 · Balance 5,380,500 F1: On October 13, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") and FPA, L.P. ("FPA Fund") purchased 2,743,902 shares, 914,634 shares and 3,048,780 shares, respectively, of the Issuer's Common Stock in a registered direct offering (the "October 2022 Offering") at a price of $1.64 per share pursuant to a Securities Purchase Agreement dated October 13, 2022. F4: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Row 4 · 2022-10-13 · Purchase · Acquired 919,111 · Balance 6,299,611 F3: Represents shares of Common Stock issued upon conversion of unsecured convertible promissory notes (the "Notes") previously held by Flagship Fund IV and Flagship Opportunities I that were issued pursuant to the terms of the Securities Purchase Agreement dated September 20, 2022. In connection with the October 2022 Offering, the conversion price of the Notes became fixed at $1.64 and the outstanding principal plus accrued interest of the Notes held by Flagship Fund IV and Flagship Opportunities I automatically converted into 2,757,333 shares and 919,111 shares, respectively, of the Issuer's Common Stock. F4: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy FPA, L.P. | 3,048,780 |
Reported balance
After 2022-10-13 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2022-10-13 · Purchase · Acquired 3,048,780 · Balance 3,048,780 F1: On October 13, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") and FPA, L.P. ("FPA Fund") purchased 2,743,902 shares, 914,634 shares and 3,048,780 shares, respectively, of the Issuer's Common Stock in a registered direct offering (the "October 2022 Offering") at a price of $1.64 per share pursuant to a Securities Purchase Agreement dated October 13, 2022. F5: Shares held by FPA Fund. FPA General Partner LLC ("FPA Fund GP") is the general partner of FPA Fund. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of FPA Fund GP. Noubar B. Afeyan, Ph.D. is the CEO and sole stockholder of Flagship Pioneering. Each of the reporting persons except for FPA Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Ventures Fund IV-Rx, L.P. | 2,004,657 |
Reported balance
Holding disclosure · report date 2022-10-13 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 2,004,657 F6: Shares held by Flagship Ventures Fund IV-Rx, L.P., ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship VentureLabs IV, LLC | 2,035,830 |
Reported balance
Holding disclosure · report date 2022-10-13 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 2,035,830 F7: Shares held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Ventures Fund 2007, L.P. | 1,761,029 |
Reported balance
Holding disclosure · report date 2022-10-13 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 1,761,029 F8: Shares held by Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007"). Flagship Ventures Fund 2007 General Partner LLC ("Fund 2007 GP") is the general partner of Flagship Fund 2007. Noubar B. Afeyan, Ph.D. is the sole manager of Fund 2007 GP. Each of the reporting persons except for Flagship Fund 2007 disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 13, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") and FPA, L.P. ("FPA Fund") purchased 2,743,902 shares, 914,634 shares and 3,048,780 shares, respectively, of the Issuer's Common Stock in a registered direct offering (the "October 2022 Offering") at a price of $1.64 per share pursuant to a Securities Purchase Agreement dated October 13, 2022.
F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F3: Represents shares of Common Stock issued upon conversion of unsecured convertible promissory notes (the "Notes") previously held by Flagship Fund IV and Flagship Opportunities I that were issued pursuant to the terms of the Securities Purchase Agreement dated September 20, 2022. In connection with the October 2022 Offering, the conversion price of the Notes became fixed at $1.64 and the outstanding principal plus accrued interest of the Notes held by Flagship Fund IV and Flagship Opportunities I automatically converted into 2,757,333 shares and 919,111 shares, respectively, of the Issuer's Common Stock.
F4: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein.
F5: Shares held by FPA Fund. FPA General Partner LLC ("FPA Fund GP") is the general partner of FPA Fund. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of FPA Fund GP. Noubar B. Afeyan, Ph.D. is the CEO and sole stockholder of Flagship Pioneering. Each of the reporting persons except for FPA Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F6: Shares held by Flagship Ventures Fund IV-Rx, L.P., ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F7: Shares held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F8: Shares held by Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007"). Flagship Ventures Fund 2007 General Partner LLC ("Fund 2007 GP") is the general partner of Flagship Fund 2007. Noubar B. Afeyan, Ph.D. is the sole manager of Fund 2007 GP. Each of the reporting persons except for Flagship Fund 2007 disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
Evelo Biosciences, Inc.
Report date May 27, 2022 · Filed June 01, 2022
Jointly reported with Flagship Ventures Fund IV General Partner LLC, Flagship Ventures Fund IV, L.P., Flagship Ventures Fund IV-Rx, L.P., Flagship Ventures Opportunities Fund I General Partner LLC, Nutritional Health LTP Fund General Partner LLC, Nutritional Health LTP Fund, L.P., Flagship Pioneering, LLC, Afeyan Noubar
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Ventures Fund IV, L.P. | 7,590,873 |
Reported balance
After 2022-05-27 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2022-05-27 · Purchase · Acquired 4,383,561 · Balance 7,590,873 F1: On May 27, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 4,383,561 shares, 1,095,890 shares, 1,369,863 shares, 6,849,315 shares and 13,698,630 shares, respectively, of the Issuer's Common Stock in a registered direct offering at a price of $1.46 per share. F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Ventures Fund IV-Rx, L.P. | 1,887,419 |
Reported balance
After 2022-05-27 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2022-05-27 · Purchase · Acquired 1,095,890 · Balance 1,887,419 F1: On May 27, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 4,383,561 shares, 1,095,890 shares, 1,369,863 shares, 6,849,315 shares and 13,698,630 shares, respectively, of the Issuer's Common Stock in a registered direct offering at a price of $1.46 per share. F3: Shares held by Flagship Fund IV-Rx. Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Ventures Opportunities Fund I, L.P. | 5,495,324 |
Reported balance
After 2022-05-27 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2022-05-27 · Purchase · Acquired 1,369,863 · Balance 5,495,324 F1: On May 27, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 4,383,561 shares, 1,095,890 shares, 1,369,863 shares, 6,849,315 shares and 13,698,630 shares, respectively, of the Issuer's Common Stock in a registered direct offering at a price of $1.46 per share. F4: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Dr. Afeyan is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Nutritional Health LTP Fund, L.P. | 8,219,791 |
Reported balance
After 2022-05-27 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2022-05-27 · Purchase · Acquired 6,849,315 · Balance 8,219,791 F1: On May 27, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 4,383,561 shares, 1,095,890 shares, 1,369,863 shares, 6,849,315 shares and 13,698,630 shares, respectively, of the Issuer's Common Stock in a registered direct offering at a price of $1.46 per share. F5: Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Dr. Afeyan is the sole member and manager of Nutritional LTP GP. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Pioneering Fund VII, L.P. | 13,698,630 |
Reported balance
After 2022-05-27 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2022-05-27 · Purchase · Acquired 13,698,630 · Balance 13,698,630 F1: On May 27, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 4,383,561 shares, 1,095,890 shares, 1,369,863 shares, 6,849,315 shares and 13,698,630 shares, respectively, of the Issuer's Common Stock in a registered direct offering at a price of $1.46 per share. F6: Shares held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Flagship Fund VII GP. Dr. Afeyan is the Chief Executive Officer, director and sole stockholder of Flagship Pioneering. Each of the reporting persons except for Flagship Fund VII disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship VentureLabs IV LLC | 684,372 |
Reported balance
Holding disclosure · report date 2022-05-27 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 684,372 F7: Shares held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship VentureLabs V LLC | 2,645,637 |
Reported balance
Holding disclosure · report date 2022-05-27 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 2,645,637 F8: Shares held by Flagship VentureLabs V LLC ("VentureLabs V"). Flagship VentureLabs V Manager LLC ("VentureLabs V Manager") serves as manager of VentureLabs V. Flagship Pioneering is the manager of VentureLabs V Manager. Dr. Afeyan is the Chief Executive Officer, director and sole stockholder of Flagship Pioneering. Each of the reporting persons except for VentureLabs V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Ventures Fund V, L.P. | 4,201,284 |
Reported balance
Holding disclosure · report date 2022-05-27 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 4,201,284 F9: Shares held by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Flagship Fund V GP") is the general partner of Flagship Fund V. Dr. Afeyan serves as sole manager of Flagship Fund V. Each of the reporting persons except for Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship V VentureLabs Rx Fund, L.P. | 1,609,871 |
Reported balance
Holding disclosure · report date 2022-05-27 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 1,609,871 F10: Shares held by Flagship V VentureLabs Rx Fund, L.P. ("VentureLabs Rx V"). Flagship Fund V GP is the general partner of VentureLabs Rx V. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for VentureLabs Rx V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Nutritional Health Side Fund, L.P. | 795,950 |
Reported balance
Holding disclosure · report date 2022-05-27 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 795,950 F11: Shares held by Nutritional Health Side Fund, L.P. ("Nutritional Health Side Fund"). Flagship Fund V GP is the general partner of Nutritional Health Side Fund. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Nutritional Health Side Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Nutritional Health Disruptive Innovation Fund, L.P. | 3,598,177 |
Reported balance
Holding disclosure · report date 2022-05-27 · row 11
Holding and transaction disclosures are not merged.
1 source rowRow 11 · Balance 3,598,177 F12: Shares held by Nutritional Health Disruptive Innovation Fund, L.P. ("Nutritional Innovation Fund"). Flagship Fund V GP is the general partner of Nutritional Innovation Fund. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Nutritional Innovation Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 27, 2022, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"), Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 4,383,561 shares, 1,095,890 shares, 1,369,863 shares, 6,849,315 shares and 13,698,630 shares, respectively, of the Issuer's Common Stock in a registered direct offering at a price of $1.46 per share.
F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F3: Shares held by Flagship Fund IV-Rx. Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F4: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Dr. Afeyan is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F5: Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Dr. Afeyan is the sole member and manager of Nutritional LTP GP. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F6: Shares held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Flagship Fund VII GP. Dr. Afeyan is the Chief Executive Officer, director and sole stockholder of Flagship Pioneering. Each of the reporting persons except for Flagship Fund VII disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F7: Shares held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F8: Shares held by Flagship VentureLabs V LLC ("VentureLabs V"). Flagship VentureLabs V Manager LLC ("VentureLabs V Manager") serves as manager of VentureLabs V. Flagship Pioneering is the manager of VentureLabs V Manager. Dr. Afeyan is the Chief Executive Officer, director and sole stockholder of Flagship Pioneering. Each of the reporting persons except for VentureLabs V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F9: Shares held by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Flagship Fund V GP") is the general partner of Flagship Fund V. Dr. Afeyan serves as sole manager of Flagship Fund V. Each of the reporting persons except for Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F10: Shares held by Flagship V VentureLabs Rx Fund, L.P. ("VentureLabs Rx V"). Flagship Fund V GP is the general partner of VentureLabs Rx V. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for VentureLabs Rx V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F11: Shares held by Nutritional Health Side Fund, L.P. ("Nutritional Health Side Fund"). Flagship Fund V GP is the general partner of Nutritional Health Side Fund. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Nutritional Health Side Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F12: Shares held by Nutritional Health Disruptive Innovation Fund, L.P. ("Nutritional Innovation Fund"). Flagship Fund V GP is the general partner of Nutritional Innovation Fund. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Nutritional Innovation Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
Foghorn Therapeutics Inc.
Report date January 13, 2026 · Filed January 15, 2026
Jointly reported with Flagship Pioneering, LLC, Flagship Pioneering Fund VII General Partner LLC, Flagship Pioneering Fund VII, L.P., Flagship Pioneering Special Opportunities Fund II General Partner LLC, Flagship Pioneering Special Opportunities Fund II, L.P., Flagship Ventures Fund V General Partner LLC, Flagship Ventures Fund V, L.P., Flagship Ventures Opportunities Fund I General Partner LLC, Afeyan Noubar
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Pre-Funded Warrants to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2046-01-13 | IndirectBy Flagship Pioneering Fund VII, L.P. | 2,235,468 |
Reported balance
After 2026-01-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-13 · Grant · Acquired 2,235,468 · Balance 2,235,468 F1: On January 13, 2026, pursuant to a registered direct offering by the Issuer, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired warrants to purchase an aggregate of 4,470,936 shares of Common Stock, consisting of (i) Pre-Funded Warrants to purchase 2,235,468 shares of Common Stock, (ii) Series 1 Warrants to purchase 1,117,734 shares of Common Stock and (iii) Series 2 Warrants to purchase 1,117,734 shares of Common Stock (together with the Series 1 Warrants, the "Series Warrants"). The securities were acquired for a purchase price of $6.7099 per Pre-Funded Warrant and accompanying Series Warrants. F2: Securities held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, LLC (f/k/a Flagship Pioneering, Inc., "Flagship Pioneering") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Series 1 Warrants to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $13.42 · Expires 2027-06-30 | IndirectBy Flagship Pioneering Fund VII, L.P. | 1,117,734 |
Reported balance
After 2026-01-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-13 · Grant · Acquired 1,117,734 · Balance 1,117,734 F3: The Series Warrants are exercisable at an initial price of $13.42 per Series 1 Warrant and $20.13 per Series 2 Warrant. Subject to certain exclusions, if prior to June 30, 2027, the Company issues capital stock or securities convertible into or exercisable for capital stock in one or more related transactions primarily for capital raising at a weighted-average common stock equivalent price (the "Weighted-Average Price") below $13.42 per share, the exercise price of a Series Warrant shall reset upon exercise to the midpoint between the initial price and the lowest such Weighted-Average Price, but not below $6.71 per share. The exercise price may be adjusted only once pursuant to this mechanism. F1: On January 13, 2026, pursuant to a registered direct offering by the Issuer, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired warrants to purchase an aggregate of 4,470,936 shares of Common Stock, consisting of (i) Pre-Funded Warrants to purchase 2,235,468 shares of Common Stock, (ii) Series 1 Warrants to purchase 1,117,734 shares of Common Stock and (iii) Series 2 Warrants to purchase 1,117,734 shares of Common Stock (together with the Series 1 Warrants, the "Series Warrants"). The securities were acquired for a purchase price of $6.7099 per Pre-Funded Warrant and accompanying Series Warrants. F2: Securities held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, LLC (f/k/a Flagship Pioneering, Inc., "Flagship Pioneering") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Series 2 Warrants to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $20.13 · Expires 2030-12-31 | IndirectBy Flagship Pioneering Fund VII, L.P. | 1,117,734 |
Reported balance
After 2026-01-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-13 · Grant · Acquired 1,117,734 · Balance 1,117,734 F3: The Series Warrants are exercisable at an initial price of $13.42 per Series 1 Warrant and $20.13 per Series 2 Warrant. Subject to certain exclusions, if prior to June 30, 2027, the Company issues capital stock or securities convertible into or exercisable for capital stock in one or more related transactions primarily for capital raising at a weighted-average common stock equivalent price (the "Weighted-Average Price") below $13.42 per share, the exercise price of a Series Warrant shall reset upon exercise to the midpoint between the initial price and the lowest such Weighted-Average Price, but not below $6.71 per share. The exercise price may be adjusted only once pursuant to this mechanism. F1: On January 13, 2026, pursuant to a registered direct offering by the Issuer, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired warrants to purchase an aggregate of 4,470,936 shares of Common Stock, consisting of (i) Pre-Funded Warrants to purchase 2,235,468 shares of Common Stock, (ii) Series 1 Warrants to purchase 1,117,734 shares of Common Stock and (iii) Series 2 Warrants to purchase 1,117,734 shares of Common Stock (together with the Series 1 Warrants, the "Series Warrants"). The securities were acquired for a purchase price of $6.7099 per Pre-Funded Warrant and accompanying Series Warrants. F2: Securities held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, LLC (f/k/a Flagship Pioneering, Inc., "Flagship Pioneering") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: On January 13, 2026, pursuant to a registered direct offering by the Issuer, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired warrants to purchase an aggregate of 4,470,936 shares of Common Stock, consisting of (i) Pre-Funded Warrants to purchase 2,235,468 shares of Common Stock, (ii) Series 1 Warrants to purchase 1,117,734 shares of Common Stock and (iii) Series 2 Warrants to purchase 1,117,734 shares of Common Stock (together with the Series 1 Warrants, the "Series Warrants"). The securities were acquired for a purchase price of $6.7099 per Pre-Funded Warrant and accompanying Series Warrants.
F2: Securities held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, LLC (f/k/a Flagship Pioneering, Inc., "Flagship Pioneering") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
F3: The Series Warrants are exercisable at an initial price of $13.42 per Series 1 Warrant and $20.13 per Series 2 Warrant. Subject to certain exclusions, if prior to June 30, 2027, the Company issues capital stock or securities convertible into or exercisable for capital stock in one or more related transactions primarily for capital raising at a weighted-average common stock equivalent price (the "Weighted-Average Price") below $13.42 per share, the exercise price of a Series Warrant shall reset upon exercise to the midpoint between the initial price and the lowest such Weighted-Average Price, but not below $6.71 per share. The exercise price may be adjusted only once pursuant to this mechanism.
Kaleido Biosciences, Inc.
Report date February 08, 2021 · Filed February 10, 2021
Jointly reported with Flagship Ventures Fund IV General Partner LLC, Flagship Ventures Fund IV, L.P., Flagship Ventures Opportunities Fund I General Partner LLC, Nutritional Health LTP Fund General Partner LLC, Nutritional Health LTP Fund, L.P., Afeyan Noubar
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,685,444 |
Reported balance
After 2021-02-08 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2021-02-08 · Purchase · Acquired 71,666 · Balance 1,685,444 F1: On February 8, 2021, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") acquired 71,666 shares pursuant to an underwritten public offering of common stock by the Issuer (the "Offering"). F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,982,639 |
Reported balance
After 2021-02-08 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2021-02-08 · Purchase · Acquired 71,667 · Balance 2,982,639 F3: On February 8, 2021, Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") acquired 71,667 shares pursuant to the Offering. F4: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Dr. Afeyan serves as sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 738,333 |
Reported balance
After 2021-02-08 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2021-02-08 · Purchase · Acquired 71,667 · Balance 738,333 F5: On February 8, 2021, Nutritional Health LTP Fund, L.P. ("Nutritional LTP") acquired 71,667 shares pursuant to the Offering. F6: Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Dr. Afeyan is the sole member and manager of Nutritional LTP GP. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 42,865 |
Reported balance
Holding disclosure · report date 2021-02-08 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 42,865 F7: Shares held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,500,000 |
Reported balance
Holding disclosure · report date 2021-02-08 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 2,500,000 F8: Shares held by Flagship VentureLabs V LLC ("VentureLabs V"). Flagship Ventures Fund V, L.P. ("Flagship Fund V") is a member of VentureLabs V. Flagship Ventures Fund V General Partner LLC ("Flagship Fund V GP") is the general partner of Flagship Fund V. Flagship VentureLabs V Manager LLC ("VentureLabs V Manager") serves as manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. Dr. Afeyan serves as sole manager of Flagship Fund V GP and as sole director of Flagship Pioneering. Each of the reporting persons except for VentureLabs V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,560,096 |
Reported balance
Holding disclosure · report date 2021-02-08 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 2,560,096 F9: Shares held by Flagship Fund V. Flagship Fund V GP is the general partner of Flagship Fund V. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 639,360 |
Reported balance
Holding disclosure · report date 2021-02-08 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 639,360 F10: Shares held by Nutritional Health Side Fund, L.P. ("Nutritional Health Side Fund"). Flagship Fund V GP is the general partner of Nutritional Health Side Fund. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Nutritional Health Side Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 6,560,523 |
Reported balance
Holding disclosure · report date 2021-02-08 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 6,560,523 F11: Shares held by Nutritional Health Disruptive Innovation Fund, L.P. ("Nutritional Innovation Fund"). Flagship Fund V GP is the general partner of Nutritional Innovation Fund. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Nutritional Innovation Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 216,451 |
Reported balance
Holding disclosure · report date 2021-02-08 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 216,451 F12: Shares held by Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007"). Flagship Ventures 2007 General Partner LLC ("Fund 2007 GP") is the general partner of Flagship Fund 2007. Dr. Afeyan is the sole manager of Fund 2007 GP. Each of the reporting persons except for Flagship Fund 2007 disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,649,999 |
Reported balance
Holding disclosure · report date 2021-02-08 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 1,649,999 F13: Shares held by Cadena LLC ("Cadena"). Dr. Afeyan is the sole manager of Cadena. Each of the reporting persons except for Cadena disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 8, 2021, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") acquired 71,666 shares pursuant to an underwritten public offering of common stock by the Issuer (the "Offering").
F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F3: On February 8, 2021, Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") acquired 71,667 shares pursuant to the Offering.
F4: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Dr. Afeyan serves as sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F5: On February 8, 2021, Nutritional Health LTP Fund, L.P. ("Nutritional LTP") acquired 71,667 shares pursuant to the Offering.
F6: Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Dr. Afeyan is the sole member and manager of Nutritional LTP GP. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F7: Shares held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F8: Shares held by Flagship VentureLabs V LLC ("VentureLabs V"). Flagship Ventures Fund V, L.P. ("Flagship Fund V") is a member of VentureLabs V. Flagship Ventures Fund V General Partner LLC ("Flagship Fund V GP") is the general partner of Flagship Fund V. Flagship VentureLabs V Manager LLC ("VentureLabs V Manager") serves as manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. Dr. Afeyan serves as sole manager of Flagship Fund V GP and as sole director of Flagship Pioneering. Each of the reporting persons except for VentureLabs V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F9: Shares held by Flagship Fund V. Flagship Fund V GP is the general partner of Flagship Fund V. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F10: Shares held by Nutritional Health Side Fund, L.P. ("Nutritional Health Side Fund"). Flagship Fund V GP is the general partner of Nutritional Health Side Fund. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Nutritional Health Side Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F11: Shares held by Nutritional Health Disruptive Innovation Fund, L.P. ("Nutritional Innovation Fund"). Flagship Fund V GP is the general partner of Nutritional Innovation Fund. Dr. Afeyan serves as sole manager of Flagship Fund V GP. Each of the reporting persons except for Nutritional Innovation Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F12: Shares held by Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007"). Flagship Ventures 2007 General Partner LLC ("Fund 2007 GP") is the general partner of Flagship Fund 2007. Dr. Afeyan is the sole manager of Fund 2007 GP. Each of the reporting persons except for Flagship Fund 2007 disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F13: Shares held by Cadena LLC ("Cadena"). Dr. Afeyan is the sole manager of Cadena. Each of the reporting persons except for Cadena disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
Rubius Therapeutics, Inc.
Report date March 19, 2021 · Filed March 23, 2021
Jointly reported with Flagship Ventures Fund IV General Partner LLC, Flagship Ventures Fund IV, L.P., Flagship Ventures Fund V General Partner LLC, Flagship Ventures Fund V, L.P., Flagship Ventures Opportunities Fund I General Partner LLC, Afeyan Noubar
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 15,393,593 |
Reported balance
After 2021-03-19 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2021-03-19 · Purchase · Acquired 70,000 · Balance 15,393,593 F1: On March 19, 2021, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") acquired 70,000 shares pursuant to an underwritten public offering of common stock by the Issuer (the "Offering"). F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Edwin M. Kania, Jr. is retired both from Flagship Pioneering, Inc. and as a manager of Flagship Fund IV GP. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 5,859,414 |
Reported balance
After 2021-03-19 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2021-03-19 · Purchase · Acquired 70,000 · Balance 5,859,414 F3: On March 19, 2021, Flagship Ventures Fund V, L.P. ("Flagship Fund V") acquired 70,000 shares pursuant to the Offering. F4: Shares held by Flagship Fund V. Flagship Ventures Fund V General Partner LLC ("Flagship Fund V GP") is the general partner of Flagship Fund V. Dr. Afeyan is the sole manager of Flagship Fund V GP. Each of the reporting persons except Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,633,703 |
Reported balance
After 2021-03-19 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2021-03-19 · Purchase · Acquired 70,000 · Balance 2,633,703 F5: On March 19, 2021, Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") acquired 70,000 shares pursuant to the Offering. F6: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Dr. Afeyan is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 5,000,000 |
Reported balance
Holding disclosure · report date 2021-03-19 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 5,000,000 F7: Shares held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 3,830,402 |
Reported balance
Holding disclosure · report date 2021-03-19 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 3,830,402 F8: Shares held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 5,789,414 |
Reported balance
Holding disclosure · report date 2021-03-19 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 5,789,414 F9: Shares held by Flagship V VentureLabs Rx Fund, L.P. ("VentureLabs Rx V"). Flagship Fund V GP is the general partner of VentureLabs Rx V. Dr. Afeyan is the sole manager of Flagship Fund V GP. Each of the reporting persons except VentureLabs Rx V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 19, 2021, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") acquired 70,000 shares pursuant to an underwritten public offering of common stock by the Issuer (the "Offering").
F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Edwin M. Kania, Jr. is retired both from Flagship Pioneering, Inc. and as a manager of Flagship Fund IV GP.
F3: On March 19, 2021, Flagship Ventures Fund V, L.P. ("Flagship Fund V") acquired 70,000 shares pursuant to the Offering.
F4: Shares held by Flagship Fund V. Flagship Ventures Fund V General Partner LLC ("Flagship Fund V GP") is the general partner of Flagship Fund V. Dr. Afeyan is the sole manager of Flagship Fund V GP. Each of the reporting persons except Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F5: On March 19, 2021, Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I") acquired 70,000 shares pursuant to the Offering.
F6: Shares held by Flagship Opportunities I. Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Dr. Afeyan is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F7: Shares held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F8: Shares held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Dr. Afeyan is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F9: Shares held by Flagship V VentureLabs Rx Fund, L.P. ("VentureLabs Rx V"). Flagship Fund V GP is the general partner of VentureLabs Rx V. Dr. Afeyan is the sole manager of Flagship Fund V GP. Each of the reporting persons except VentureLabs Rx V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionSeries E Preferred Stock · Derivative | 89,525 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · derivative · entry 24 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 48,602 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each share of Series E Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F8 · price: Each share of Series E Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F8 · derivative.exercise_date: Each share of Series E Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F8 · derivative.expiration_date: Each share of Series E Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F6 · ownership.nature: Shares held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Fund IV GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship Fund IV GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund IV-Rx. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionSeries E Preferred Stock · Derivative | 358,102 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · derivative · entry 23 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 194,409 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each share of Series E Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F8 · price: Each share of Series E Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F8 · derivative.exercise_date: Each share of Series E Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F8 · derivative.expiration_date: Each share of Series E Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F4 · ownership.nature: Shares held by Flagship Fund IV. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Fund IV GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship Fund IV GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund IV. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionSeries C Preferred Stock · Derivative | 151,643 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · derivative · entry 22 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 82,324 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F7 · price: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F7 · derivative.exercise_date: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F7 · derivative.expiration_date: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F6 · ownership.nature: Shares held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Fund IV GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship Fund IV GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund IV-Rx. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionSeries C Preferred Stock · Derivative | 617,914 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · derivative · entry 21 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 335,457 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F7 · price: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F7 · derivative.exercise_date: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F7 · derivative.expiration_date: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F4 · ownership.nature: Shares held by Flagship Fund IV. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Fund IV GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship Fund IV GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund IV. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionSeries C Preferred Stock · Derivative | 222,506 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · derivative · entry 20 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 120,795 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F7 · price: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F7 · derivative.exercise_date: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F7 · derivative.expiration_date: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F1 · ownership.nature: Shares held by Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007"). Flagship Ventures 2007 General Partner LLC ("Fund 2007 GP") is the general partner of Flagship Fund 2007. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Fund 2007 GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship 2007 GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund 2007. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionSeries B Preferred Stock · Derivative | 1,005,413 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · derivative · entry 19 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 545,826 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F5 · price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F5 · derivative.exercise_date: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F5 · derivative.expiration_date: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F6 · ownership.nature: Shares held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Fund IV GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship Fund IV GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund IV-Rx. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionSeries B Preferred Stock · Derivative | 928,074 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · derivative · entry 18 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 503,840 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F5 · price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F5 · derivative.exercise_date: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F5 · derivative.expiration_date: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F4 · ownership.nature: Shares held by Flagship Fund IV. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Fund IV GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship Fund IV GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund IV. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionSeries B Preferred Stock · Derivative | 386,697 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · derivative · entry 17 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 209,933 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F5 · price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F5 · derivative.exercise_date: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F5 · derivative.expiration_date: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F1 · ownership.nature: Shares held by Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007"). Flagship Ventures 2007 General Partner LLC ("Fund 2007 GP") is the general partner of Flagship Fund 2007. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Fund 2007 GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship 2007 GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund 2007. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionSeries A Preferred Stock · Derivative | 4,153,847 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · derivative · entry 16 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 2,255,074 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F3 · price: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F3 · derivative.exercise_date: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F3 · derivative.expiration_date: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F4 · ownership.nature: Shares held by Flagship Fund IV. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Fund IV GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship Fund IV GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund IV. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionSeries A Preferred Stock · Derivative | 1,384,615 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · derivative · entry 15 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 751,691 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F3 · price: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F3 · derivative.exercise_date: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F3 · derivative.expiration_date: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F1 · ownership.nature: Shares held by Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007"). Flagship Ventures 2007 General Partner LLC ("Fund 2007 GP") is the general partner of Flagship Fund 2007. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Fund 2007 GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship 2007 GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund 2007. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | PurchaseCommon Stock | 500,000 | $20.00 | $10,000,000.00 |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · nonDerivative · entry 14 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 986,023 F9 · ownership.nature: Shares held by Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"). Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Noubar B. Afeyan, Ph.D. serves as sole manager of Flagship Opportunities GP and may be deemed to possess sole voting and investment power with respect to all shares held by Flagship Opportunities I. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionCommon Stock | 486,023 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · nonDerivative · entry 13 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 486,023 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · price: Each share of Series E Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F9 · ownership.nature: Shares held by Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"). Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Noubar B. Afeyan, Ph.D. serves as sole manager of Flagship Opportunities GP and may be deemed to possess sole voting and investment power with respect to all shares held by Flagship Opportunities I. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionCommon Stock | 48,602 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · nonDerivative · entry 12 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 676,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · price: Each share of Series E Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F6 · ownership.nature: Shares held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Fund IV GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship Fund IV GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund IV-Rx. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionCommon Stock | 194,409 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · nonDerivative · entry 11 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,288,780 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · price: Each share of Series E Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F4 · ownership.nature: Shares held by Flagship Fund IV. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Fund IV GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship Fund IV GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund IV. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionCommon Stock | 82,324 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · nonDerivative · entry 10 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 628,150 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F6 · ownership.nature: Shares held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Fund IV GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship Fund IV GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund IV-Rx. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionCommon Stock | 335,457 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · nonDerivative · entry 9 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,094,371 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F4 · ownership.nature: Shares held by Flagship Fund IV. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Fund IV GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship Fund IV GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund IV. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionCommon Stock | 120,795 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · nonDerivative · entry 8 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,761,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F1 · ownership.nature: Shares held by Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007"). Flagship Ventures 2007 General Partner LLC ("Fund 2007 GP") is the general partner of Flagship Fund 2007. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Fund 2007 GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship 2007 GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund 2007. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionCommon Stock | 545,826 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · nonDerivative · entry 7 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 545,826 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F6 · ownership.nature: Shares held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Fund IV GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship Fund IV GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund IV-Rx. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionCommon Stock | 503,840 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · nonDerivative · entry 6 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,758,914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F4 · ownership.nature: Shares held by Flagship Fund IV. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Fund IV GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship Fund IV GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund IV. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionCommon Stock | 209,933 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · nonDerivative · entry 5 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,640,234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F1 · ownership.nature: Shares held by Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007"). Flagship Ventures 2007 General Partner LLC ("Fund 2007 GP") is the general partner of Flagship Fund 2007. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Fund 2007 GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship 2007 GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund 2007. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionCommon Stock | 2,255,074 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · nonDerivative · entry 4 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,255,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F4 · ownership.nature: Shares held by Flagship Fund IV. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Fund IV GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship Fund IV GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund IV. Each of the reporting persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:18 UTC | Axcella Health Inc. AXLA · Entity 116059 | ConversionCommon Stock | 751,691 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-029735 · a4.xml · nonDerivative · entry 3 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures 2007 General Partner LLC · CIK 0001508053 · 10% owner Flagship Ventures Fund 2007, L.P. · CIK 0001508052 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,430,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-1.842 basis upon the closing of the Issuer's initial public offering. F1 · ownership.nature: Shares held by Flagship Ventures Fund 2007, L.P. ("Flagship Fund 2007"). Flagship Ventures 2007 General Partner LLC ("Fund 2007 GP") is the general partner of Flagship Fund 2007. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Fund 2007 GP. While Mr. Kania is retired from Flagship Pioneering, Inc., he continues to serve as a manager of Flagship 2007 GP. Each of these individuals and entities may be deemed to share voting and investment power with respect to all shares held by Flagship Fund 2007. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 16:45 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | ConversionSeries C Preferred Stock · Derivative | 1,251,251 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-006455 · doc4.xml · derivative · entry 22 Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · Director · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship VentureLabs V LLC · CIK 0001724959 · 10% owner Flagship VentureLabs V Manager LLC · CIK 0001768987 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Nutritional Health Disruptive Innovation Fund, L.P. · CIK 0001725001 · 10% owner Nutritional Health Side Fund, L.P. · CIK 0001725000 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 625,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-two basis upon the closing of the Issuer's initial public offering. F8 · price: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-two basis upon the closing of the Issuer's initial public offering. F8 · derivative.exercise_date: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-two basis upon the closing of the Issuer's initial public offering. F8 · derivative.expiration_date: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-two basis upon the closing of the Issuer's initial public offering. F9 · ownership.nature: Shares held by Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"). Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Noubar B. Afeyan, Ph.D. serves as sole manager of Flagship Opportunities GP and may be deemed to possess sole voting and investment power with respect to all shares held by Flagship Opportunities I. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 16:45 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | ConversionSeries C Preferred Stock · Derivative | 1,251,251 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-006455 · doc4.xml · derivative · entry 21 Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · Director · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship VentureLabs V LLC · CIK 0001724959 · 10% owner Flagship VentureLabs V Manager LLC · CIK 0001768987 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Nutritional Health Disruptive Innovation Fund, L.P. · CIK 0001725001 · 10% owner Nutritional Health Side Fund, L.P. · CIK 0001725000 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 625,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-two basis upon the closing of the Issuer's initial public offering. F8 · price: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-two basis upon the closing of the Issuer's initial public offering. F8 · derivative.exercise_date: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-two basis upon the closing of the Issuer's initial public offering. F8 · derivative.expiration_date: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-two basis upon the closing of the Issuer's initial public offering. F4 · ownership.nature: Shares held by Nutritional Health Disruptive Innovation Fund, L.P. ("Nutritional Innovation Fund"). Flagship Fund V GP is the general partner of Nutritional Innovation Fund. Noubar B. Afeyan, Ph.D. serves as sole manager of Flagship Fund V GP and may be deemed to possess sole voting and investment power with respect to all shares held by Nutritional Innovation Fund. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 16:45 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | ConversionSeries B Preferred Stock · Derivative | 2,570,694 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-006455 · doc4.xml · derivative · entry 20 Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · Director · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship VentureLabs V LLC · CIK 0001724959 · 10% owner Flagship VentureLabs V Manager LLC · CIK 0001768987 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Nutritional Health Disruptive Innovation Fund, L.P. · CIK 0001725001 · 10% owner Nutritional Health Side Fund, L.P. · CIK 0001725000 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,285,347 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-two basis upon the closing of the Issuer's initial public offering. F7 · price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-two basis upon the closing of the Issuer's initial public offering. F7 · derivative.exercise_date: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-two basis upon the closing of the Issuer's initial public offering. F7 · derivative.expiration_date: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-two basis upon the closing of the Issuer's initial public offering. F9 · ownership.nature: Shares held by Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"). Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Noubar B. Afeyan, Ph.D. serves as sole manager of Flagship Opportunities GP and may be deemed to possess sole voting and investment power with respect to all shares held by Flagship Opportunities I. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 16:45 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | ConversionSeries B Preferred Stock · Derivative | 1,928,021 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-006455 · doc4.xml · derivative · entry 19 Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · Director · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship VentureLabs V LLC · CIK 0001724959 · 10% owner Flagship VentureLabs V Manager LLC · CIK 0001768987 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Nutritional Health Disruptive Innovation Fund, L.P. · CIK 0001725001 · 10% owner Nutritional Health Side Fund, L.P. · CIK 0001725000 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 964,010 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-two basis upon the closing of the Issuer's initial public offering. F7 · price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-two basis upon the closing of the Issuer's initial public offering. F7 · derivative.exercise_date: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-two basis upon the closing of the Issuer's initial public offering. F7 · derivative.expiration_date: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-two basis upon the closing of the Issuer's initial public offering. F4 · ownership.nature: Shares held by Nutritional Health Disruptive Innovation Fund, L.P. ("Nutritional Innovation Fund"). Flagship Fund V GP is the general partner of Nutritional Innovation Fund. Noubar B. Afeyan, Ph.D. serves as sole manager of Flagship Fund V GP and may be deemed to possess sole voting and investment power with respect to all shares held by Nutritional Innovation Fund. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 16:45 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | ConversionSeries B Preferred Stock · Derivative | 642,674 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-006455 · doc4.xml · derivative · entry 18 Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · Director · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship VentureLabs V LLC · CIK 0001724959 · 10% owner Flagship VentureLabs V Manager LLC · CIK 0001768987 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Nutritional Health Disruptive Innovation Fund, L.P. · CIK 0001725001 · 10% owner Nutritional Health Side Fund, L.P. · CIK 0001725000 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 321,337 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-two basis upon the closing of the Issuer's initial public offering. F7 · price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-two basis upon the closing of the Issuer's initial public offering. F7 · derivative.exercise_date: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-two basis upon the closing of the Issuer's initial public offering. F7 · derivative.expiration_date: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-two basis upon the closing of the Issuer's initial public offering. F3 · ownership.nature: Shares held by Flagship Fund V. Flagship Fund V GP is the general partner of Flagship Fund V. Noubar B. Afeyan, Ph.D. serves as sole manager of Flagship Fund V GP and may be deemed to possess sole voting and investment power with respect to all shares held by Flagship Fund V. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 16:45 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | ConversionSeries A-1 Preferred Stock · Derivative | 1,278,720 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-006455 · doc4.xml · derivative · entry 17 Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · Director · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship VentureLabs V LLC · CIK 0001724959 · 10% owner Flagship VentureLabs V Manager LLC · CIK 0001768987 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Nutritional Health Disruptive Innovation Fund, L.P. · CIK 0001725001 · 10% owner Nutritional Health Side Fund, L.P. · CIK 0001725000 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 639,360 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of Series A-1 Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-two basis upon the closing of the Issuer's initial public offering. F5 · price: Each share of Series A-1 Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-two basis upon the closing of the Issuer's initial public offering. F5 · derivative.exercise_date: Each share of Series A-1 Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-two basis upon the closing of the Issuer's initial public offering. F5 · derivative.expiration_date: Each share of Series A-1 Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-two basis upon the closing of the Issuer's initial public offering. F6 · ownership.nature: Shares held by Nutritional Health Side Fund, L.P. ("Nutritional Health Side Fund"). Flagship Fund V GP is the general partner of Nutritional Health Side Fund. Noubar B. Afeyan, Ph.D. serves as sole manager of Flagship Fund V GP and may be deemed to possess sole voting and investment power with respect to all shares held by Nutritional Health Side Fund. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 16:45 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | ConversionSeries A-1 Preferred Stock · Derivative | 852,480 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-006455 · doc4.xml · derivative · entry 16 Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · Director · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship VentureLabs V LLC · CIK 0001724959 · 10% owner Flagship VentureLabs V Manager LLC · CIK 0001768987 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Nutritional Health Disruptive Innovation Fund, L.P. · CIK 0001725001 · 10% owner Nutritional Health Side Fund, L.P. · CIK 0001725000 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 426,240 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of Series A-1 Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-two basis upon the closing of the Issuer's initial public offering. F5 · price: Each share of Series A-1 Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-two basis upon the closing of the Issuer's initial public offering. F5 · derivative.exercise_date: Each share of Series A-1 Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-two basis upon the closing of the Issuer's initial public offering. F5 · derivative.expiration_date: Each share of Series A-1 Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-two basis upon the closing of the Issuer's initial public offering. F3 · ownership.nature: Shares held by Flagship Fund V. Flagship Fund V GP is the general partner of Flagship Fund V. Noubar B. Afeyan, Ph.D. serves as sole manager of Flagship Fund V GP and may be deemed to possess sole voting and investment power with respect to all shares held by Flagship Fund V. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 16:45 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | ConversionSeries A Preferred Stock · Derivative | 9,275,111 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-006455 · doc4.xml · derivative · entry 15 Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · Director · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship VentureLabs V LLC · CIK 0001724959 · 10% owner Flagship VentureLabs V Manager LLC · CIK 0001768987 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Nutritional Health Disruptive Innovation Fund, L.P. · CIK 0001725001 · 10% owner Nutritional Health Side Fund, L.P. · CIK 0001725000 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 4,637,555 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.001 ("Common Stock"), on a one-for-two basis upon the closing of the Issuer's initial public offering. F2 · price: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.001 ("Common Stock"), on a one-for-two basis upon the closing of the Issuer's initial public offering. F2 · derivative.exercise_date: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.001 ("Common Stock"), on a one-for-two basis upon the closing of the Issuer's initial public offering. F2 · derivative.expiration_date: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.001 ("Common Stock"), on a one-for-two basis upon the closing of the Issuer's initial public offering. F4 · ownership.nature: Shares held by Nutritional Health Disruptive Innovation Fund, L.P. ("Nutritional Innovation Fund"). Flagship Fund V GP is the general partner of Nutritional Innovation Fund. Noubar B. Afeyan, Ph.D. serves as sole manager of Flagship Fund V GP and may be deemed to possess sole voting and investment power with respect to all shares held by Nutritional Innovation Fund. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 16:45 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | ConversionSeries A Preferred Stock · Derivative | 3,091,704 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-006455 · doc4.xml · derivative · entry 14 Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · Director · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship VentureLabs V LLC · CIK 0001724959 · 10% owner Flagship VentureLabs V Manager LLC · CIK 0001768987 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Nutritional Health Disruptive Innovation Fund, L.P. · CIK 0001725001 · 10% owner Nutritional Health Side Fund, L.P. · CIK 0001725000 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,545,852 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.001 ("Common Stock"), on a one-for-two basis upon the closing of the Issuer's initial public offering. F2 · price: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.001 ("Common Stock"), on a one-for-two basis upon the closing of the Issuer's initial public offering. F2 · derivative.exercise_date: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.001 ("Common Stock"), on a one-for-two basis upon the closing of the Issuer's initial public offering. F2 · derivative.expiration_date: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.001 ("Common Stock"), on a one-for-two basis upon the closing of the Issuer's initial public offering. F3 · ownership.nature: Shares held by Flagship Fund V. Flagship Fund V GP is the general partner of Flagship Fund V. Noubar B. Afeyan, Ph.D. serves as sole manager of Flagship Fund V GP and may be deemed to possess sole voting and investment power with respect to all shares held by Flagship Fund V. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 16:45 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | PurchaseCommon Stock | 333,333 | $15.00 | $4,999,995.00 |
DisclosureSEC source: 0000899243-19-006455 · doc4.xml · nonDerivative · entry 13 Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · Director · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship VentureLabs V LLC · CIK 0001724959 · 10% owner Flagship VentureLabs V Manager LLC · CIK 0001768987 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Nutritional Health Disruptive Innovation Fund, L.P. · CIK 0001725001 · 10% owner Nutritional Health Side Fund, L.P. · CIK 0001725000 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,244,305 F9 · ownership.nature: Shares held by Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"). Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Noubar B. Afeyan, Ph.D. serves as sole manager of Flagship Opportunities GP and may be deemed to possess sole voting and investment power with respect to all shares held by Flagship Opportunities I. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 16:45 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | PurchaseCommon Stock | 333,333 | $15.00 | $4,999,995.00 |
DisclosureSEC source: 0000899243-19-006455 · doc4.xml · nonDerivative · entry 12 Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · Director · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship VentureLabs V LLC · CIK 0001724959 · 10% owner Flagship VentureLabs V Manager LLC · CIK 0001768987 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Nutritional Health Disruptive Innovation Fund, L.P. · CIK 0001725001 · 10% owner Nutritional Health Side Fund, L.P. · CIK 0001725000 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,560,523 F4 · ownership.nature: Shares held by Nutritional Health Disruptive Innovation Fund, L.P. ("Nutritional Innovation Fund"). Flagship Fund V GP is the general partner of Nutritional Innovation Fund. Noubar B. Afeyan, Ph.D. serves as sole manager of Flagship Fund V GP and may be deemed to possess sole voting and investment power with respect to all shares held by Nutritional Innovation Fund. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 16:45 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | PurchaseCommon Stock | 266,667 | $15.00 | $4,000,005.00 |
DisclosureSEC source: 0000899243-19-006455 · doc4.xml · nonDerivative · entry 11 Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · Director · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship VentureLabs V LLC · CIK 0001724959 · 10% owner Flagship VentureLabs V Manager LLC · CIK 0001768987 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Nutritional Health Disruptive Innovation Fund, L.P. · CIK 0001725001 · 10% owner Nutritional Health Side Fund, L.P. · CIK 0001725000 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,560,096 F3 · ownership.nature: Shares held by Flagship Fund V. Flagship Fund V GP is the general partner of Flagship Fund V. Noubar B. Afeyan, Ph.D. serves as sole manager of Flagship Fund V GP and may be deemed to possess sole voting and investment power with respect to all shares held by Flagship Fund V. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 16:45 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | ConversionCommon Stock | 625,625 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-006455 · doc4.xml · nonDerivative · entry 10 Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · Director · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship VentureLabs V LLC · CIK 0001724959 · 10% owner Flagship VentureLabs V Manager LLC · CIK 0001768987 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Nutritional Health Disruptive Innovation Fund, L.P. · CIK 0001725001 · 10% owner Nutritional Health Side Fund, L.P. · CIK 0001725000 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,910,972 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · price: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-two basis upon the closing of the Issuer's initial public offering. F9 · ownership.nature: Shares held by Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"). Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Noubar B. Afeyan, Ph.D. serves as sole manager of Flagship Opportunities GP and may be deemed to possess sole voting and investment power with respect to all shares held by Flagship Opportunities I. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 16:45 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | ConversionCommon Stock | 625,625 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-006455 · doc4.xml · nonDerivative · entry 9 Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · Director · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship VentureLabs V LLC · CIK 0001724959 · 10% owner Flagship VentureLabs V Manager LLC · CIK 0001768987 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Nutritional Health Disruptive Innovation Fund, L.P. · CIK 0001725001 · 10% owner Nutritional Health Side Fund, L.P. · CIK 0001725000 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 6,227,190 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · price: Each share of Series C Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-two basis upon the closing of the Issuer's initial public offering. F4 · ownership.nature: Shares held by Nutritional Health Disruptive Innovation Fund, L.P. ("Nutritional Innovation Fund"). Flagship Fund V GP is the general partner of Nutritional Innovation Fund. Noubar B. Afeyan, Ph.D. serves as sole manager of Flagship Fund V GP and may be deemed to possess sole voting and investment power with respect to all shares held by Nutritional Innovation Fund. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 16:45 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | ConversionCommon Stock | 1,285,347 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-006455 · doc4.xml · nonDerivative · entry 8 Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · Director · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship VentureLabs V LLC · CIK 0001724959 · 10% owner Flagship VentureLabs V Manager LLC · CIK 0001768987 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Nutritional Health Disruptive Innovation Fund, L.P. · CIK 0001725001 · 10% owner Nutritional Health Side Fund, L.P. · CIK 0001725000 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,285,347 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-two basis upon the closing of the Issuer's initial public offering. F9 · ownership.nature: Shares held by Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"). Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Noubar B. Afeyan, Ph.D. serves as sole manager of Flagship Opportunities GP and may be deemed to possess sole voting and investment power with respect to all shares held by Flagship Opportunities I. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 16:45 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | ConversionCommon Stock | 964,010 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-006455 · doc4.xml · nonDerivative · entry 7 Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · Director · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship VentureLabs V LLC · CIK 0001724959 · 10% owner Flagship VentureLabs V Manager LLC · CIK 0001768987 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Nutritional Health Disruptive Innovation Fund, L.P. · CIK 0001725001 · 10% owner Nutritional Health Side Fund, L.P. · CIK 0001725000 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,601,565 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-two basis upon the closing of the Issuer's initial public offering. F4 · ownership.nature: Shares held by Nutritional Health Disruptive Innovation Fund, L.P. ("Nutritional Innovation Fund"). Flagship Fund V GP is the general partner of Nutritional Innovation Fund. Noubar B. Afeyan, Ph.D. serves as sole manager of Flagship Fund V GP and may be deemed to possess sole voting and investment power with respect to all shares held by Nutritional Innovation Fund. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 16:45 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | ConversionCommon Stock | 321,337 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-006455 · doc4.xml · nonDerivative · entry 6 Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · Director · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship VentureLabs V LLC · CIK 0001724959 · 10% owner Flagship VentureLabs V Manager LLC · CIK 0001768987 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Nutritional Health Disruptive Innovation Fund, L.P. · CIK 0001725001 · 10% owner Nutritional Health Side Fund, L.P. · CIK 0001725000 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,293,429 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-two basis upon the closing of the Issuer's initial public offering. F3 · ownership.nature: Shares held by Flagship Fund V. Flagship Fund V GP is the general partner of Flagship Fund V. Noubar B. Afeyan, Ph.D. serves as sole manager of Flagship Fund V GP and may be deemed to possess sole voting and investment power with respect to all shares held by Flagship Fund V. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 16:45 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | ConversionCommon Stock | 639,360 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-006455 · doc4.xml · nonDerivative · entry 5 Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · Director · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship VentureLabs V LLC · CIK 0001724959 · 10% owner Flagship VentureLabs V Manager LLC · CIK 0001768987 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Nutritional Health Disruptive Innovation Fund, L.P. · CIK 0001725001 · 10% owner Nutritional Health Side Fund, L.P. · CIK 0001725000 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 639,360 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each share of Series A-1 Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-two basis upon the closing of the Issuer's initial public offering. F6 · ownership.nature: Shares held by Nutritional Health Side Fund, L.P. ("Nutritional Health Side Fund"). Flagship Fund V GP is the general partner of Nutritional Health Side Fund. Noubar B. Afeyan, Ph.D. serves as sole manager of Flagship Fund V GP and may be deemed to possess sole voting and investment power with respect to all shares held by Nutritional Health Side Fund. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 16:45 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | ConversionCommon Stock | 426,240 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-006455 · doc4.xml · nonDerivative · entry 4 Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · Director · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship VentureLabs V LLC · CIK 0001724959 · 10% owner Flagship VentureLabs V Manager LLC · CIK 0001768987 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Nutritional Health Disruptive Innovation Fund, L.P. · CIK 0001725001 · 10% owner Nutritional Health Side Fund, L.P. · CIK 0001725000 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,972,092 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each share of Series A-1 Preferred Stock converted into shares of the Issuer's Common Stock on a one-for-two basis upon the closing of the Issuer's initial public offering. F3 · ownership.nature: Shares held by Flagship Fund V. Flagship Fund V GP is the general partner of Flagship Fund V. Noubar B. Afeyan, Ph.D. serves as sole manager of Flagship Fund V GP and may be deemed to possess sole voting and investment power with respect to all shares held by Flagship Fund V. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 16:45 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | ConversionCommon Stock | 4,637,555 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-006455 · doc4.xml · nonDerivative · entry 3 Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · Director · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship VentureLabs V LLC · CIK 0001724959 · 10% owner Flagship VentureLabs V Manager LLC · CIK 0001768987 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Nutritional Health Disruptive Innovation Fund, L.P. · CIK 0001725001 · 10% owner Nutritional Health Side Fund, L.P. · CIK 0001725000 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,637,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.001 ("Common Stock"), on a one-for-two basis upon the closing of the Issuer's initial public offering. F4 · ownership.nature: Shares held by Nutritional Health Disruptive Innovation Fund, L.P. ("Nutritional Innovation Fund"). Flagship Fund V GP is the general partner of Nutritional Innovation Fund. Noubar B. Afeyan, Ph.D. serves as sole manager of Flagship Fund V GP and may be deemed to possess sole voting and investment power with respect to all shares held by Nutritional Innovation Fund. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 16:45 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | ConversionCommon Stock | 1,545,852 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-006455 · doc4.xml · nonDerivative · entry 2 Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · Director · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship VentureLabs V LLC · CIK 0001724959 · 10% owner Flagship VentureLabs V Manager LLC · CIK 0001768987 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Nutritional Health Disruptive Innovation Fund, L.P. · CIK 0001725001 · 10% owner Nutritional Health Side Fund, L.P. · CIK 0001725000 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,545,852 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.001 ("Common Stock"), on a one-for-two basis upon the closing of the Issuer's initial public offering. F3 · ownership.nature: Shares held by Flagship Fund V. Flagship Fund V GP is the general partner of Flagship Fund V. Noubar B. Afeyan, Ph.D. serves as sole manager of Flagship Fund V GP and may be deemed to possess sole voting and investment power with respect to all shares held by Flagship Fund V. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| July 20, 2018 Filed Jul 23, 2018 16:34 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | ConversionSeries C Preferred Stock · Derivative | 781,860 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-046534 · a4.xml · derivative · entry 21 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · Director · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship V VentureLabs Rx Fund, L.P. · CIK 0001724939 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 781,860 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock automatically convert into common stock upon the closing of the Issuer's initial public offering held on July 20, 2018. F2 · price: The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock automatically convert into common stock upon the closing of the Issuer's initial public offering held on July 20, 2018. F2 · derivative.exercise_date: The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock automatically convert into common stock upon the closing of the Issuer's initial public offering held on July 20, 2018. F2 · derivative.expiration_date: The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock automatically convert into common stock upon the closing of the Issuer's initial public offering held on July 20, 2018. F7 · ownership.nature: Shares held by Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities Fund I"). Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Opportunities GP and may be deemed to possess sole voting and investment power with respect to all shares held by Flagship Opportunities I. Each of the filing persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| July 20, 2018 Filed Jul 23, 2018 16:34 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | ConversionSeries C Preferred Stock · Derivative | 195,466 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-046534 · a4.xml · derivative · entry 20 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · Director · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship V VentureLabs Rx Fund, L.P. · CIK 0001724939 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 195,466 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock automatically convert into common stock upon the closing of the Issuer's initial public offering held on July 20, 2018. F2 · price: The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock automatically convert into common stock upon the closing of the Issuer's initial public offering held on July 20, 2018. F2 · derivative.exercise_date: The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock automatically convert into common stock upon the closing of the Issuer's initial public offering held on July 20, 2018. F2 · derivative.expiration_date: The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock automatically convert into common stock upon the closing of the Issuer's initial public offering held on July 20, 2018. F6 · ownership.nature: Shares held by Flagship V VentureLabs Rx Fund, L.P. ("VentureLabs Rx V"). Flagship Fund V GP is the general partner of VentureLabs Rx V. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund V GP and may be deemed to possess sole voting and investment power with respect to all shares held by VentureLabs Rx V. Each of the filing persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| July 20, 2018 Filed Jul 23, 2018 16:34 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | ConversionSeries C Preferred Stock · Derivative | 195,466 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-046534 · a4.xml · derivative · entry 19 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · Director · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship V VentureLabs Rx Fund, L.P. · CIK 0001724939 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 195,466 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock automatically convert into common stock upon the closing of the Issuer's initial public offering held on July 20, 2018. F2 · price: The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock automatically convert into common stock upon the closing of the Issuer's initial public offering held on July 20, 2018. F2 · derivative.exercise_date: The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock automatically convert into common stock upon the closing of the Issuer's initial public offering held on July 20, 2018. F2 · derivative.expiration_date: The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock automatically convert into common stock upon the closing of the Issuer's initial public offering held on July 20, 2018. F5 · ownership.nature: Shares held by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Flagship Fund V GP") is the general partner of Flagship Fund V. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund V GP and may be deemed to possess sole voting and investment power with respect to all shares held by Flagship Fund V. Each of the filing persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| July 20, 2018 Filed Jul 23, 2018 16:34 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | ConversionSeries B Preferred Stock · Derivative | 1,781,843 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-046534 · a4.xml · derivative · entry 18 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · Director · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship V VentureLabs Rx Fund, L.P. · CIK 0001724939 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,781,843 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock automatically convert into common stock upon the closing of the Issuer's initial public offering held on July 20, 2018. F2 · price: The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock automatically convert into common stock upon the closing of the Issuer's initial public offering held on July 20, 2018. F2 · derivative.exercise_date: The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock automatically convert into common stock upon the closing of the Issuer's initial public offering held on July 20, 2018. F2 · derivative.expiration_date: The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock automatically convert into common stock upon the closing of the Issuer's initial public offering held on July 20, 2018. F7 · ownership.nature: Shares held by Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities Fund I"). Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Opportunities GP and may be deemed to possess sole voting and investment power with respect to all shares held by Flagship Opportunities I. Each of the filing persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| July 20, 2018 Filed Jul 23, 2018 16:34 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | ConversionSeries B Preferred Stock · Derivative | 593,948 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-046534 · a4.xml · derivative · entry 17 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · Director · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship V VentureLabs Rx Fund, L.P. · CIK 0001724939 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 593,948 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock automatically convert into common stock upon the closing of the Issuer's initial public offering held on July 20, 2018. F2 · price: The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock automatically convert into common stock upon the closing of the Issuer's initial public offering held on July 20, 2018. F2 · derivative.exercise_date: The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock automatically convert into common stock upon the closing of the Issuer's initial public offering held on July 20, 2018. F2 · derivative.expiration_date: The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock automatically convert into common stock upon the closing of the Issuer's initial public offering held on July 20, 2018. F6 · ownership.nature: Shares held by Flagship V VentureLabs Rx Fund, L.P. ("VentureLabs Rx V"). Flagship Fund V GP is the general partner of VentureLabs Rx V. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund V GP and may be deemed to possess sole voting and investment power with respect to all shares held by VentureLabs Rx V. Each of the filing persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| July 20, 2018 Filed Jul 23, 2018 16:34 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | ConversionSeries B Preferred Stock · Derivative | 593,948 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-046534 · a4.xml · derivative · entry 16 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · Director · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship V VentureLabs Rx Fund, L.P. · CIK 0001724939 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 593,948 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock automatically convert into common stock upon the closing of the Issuer's initial public offering held on July 20, 2018. F2 · price: The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock automatically convert into common stock upon the closing of the Issuer's initial public offering held on July 20, 2018. F2 · derivative.exercise_date: The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock automatically convert into common stock upon the closing of the Issuer's initial public offering held on July 20, 2018. F2 · derivative.expiration_date: The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock automatically convert into common stock upon the closing of the Issuer's initial public offering held on July 20, 2018. F5 · ownership.nature: Shares held by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Flagship Fund V GP") is the general partner of Flagship Fund V. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund V GP and may be deemed to possess sole voting and investment power with respect to all shares held by Flagship Fund V. Each of the filing persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| July 20, 2018 Filed Jul 23, 2018 16:34 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | ConversionSeries A Preferred Stock · Derivative | 5,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-046534 · a4.xml · derivative · entry 15 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · Director · 10% owner Flagship VentureLabs IV, LLC · CIK 0001642578 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · 10% owner Flagship V VentureLabs Rx Fund, L.P. · CIK 0001724939 · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner KANIA EDWIN M JR · CIK 0001255927 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 5,000,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock automatically convert into common stock upon the closing of the Issuer's initial public offering held on July 20, 2018. F2 · price: The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock automatically convert into common stock upon the closing of the Issuer's initial public offering held on July 20, 2018. F2 · derivative.exercise_date: The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock automatically convert into common stock upon the closing of the Issuer's initial public offering held on July 20, 2018. F2 · derivative.expiration_date: The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock automatically convert into common stock upon the closing of the Issuer's initial public offering held on July 20, 2018. F6 · ownership.nature: Shares held by Flagship V VentureLabs Rx Fund, L.P. ("VentureLabs Rx V"). Flagship Fund V GP is the general partner of VentureLabs Rx V. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund V GP and may be deemed to possess sole voting and investment power with respect to all shares held by VentureLabs Rx V. Each of the filing persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.